Skip to main content

Table 2 Anthropometric, clinical and biochemical variables classified according to ISUP GG patient classification

From: Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness

 

ISUP GG classification

Low risk (group I and II)

High risk (group III, IV and V)

p-value

Mean ± SD

Mean ± SD

Anthropometric parameters

 Age (years)

62.82 ± 6.8

64.55 ± 5.82

0.320

 BMI (kg/m2)

28.23 ± 4.05

27.94 ± 3.54

0.665

 Prostatic volume (cc)

45.71 ± 25.96

43.5 ± 19.52

0.716

Glycemic profile

 Glucose (mmol/L)

5.90 ± 1.23

6.65 ± 2.35

0.050

 Insulin (pmol/L)

95.42 ± 60.84

89.73 ± 48.41

0.847

 HOMA-IR

3.75 ± 2.92

3.92 ± 2.76

0.795

 HbA1c (%)

5.77 ± 0.67

6.01 ± 0.86

0.152

Lipid profile

 Cholesterol (mmol/L)

5.02 ± 1.06

4.93 ± 1.01

0.609

 HDL cholesterol (mmol/L)

1.49 ± 0.71

1.35 ± 0.39

0.484

 LDL cholesterol (mmol/L)

3.23 ± 1.29

2.84 ± 0.88

0.148

 Triglycerides (mmol/L)

1.40 ± 0.74

1.63 ± 0.99

0.526

Hepatic profile

 AST (µkat/L)

0.38 ± 0.19

0.32 ± 0.07

0.104

 ALT (µkat/L)

0.40 ± 0.21

0.36 ± 0.11

0.816

 GGT (µkat/L)

0.72 ± 0.88

0.68 ± 0.50

0.783

Renal profile

 Uric acid (µmol/L)

373.57 ± 88.63

463.39 ± 559.75

0.595

 Urea (mmol/L)

13.99 ± 3.34

14.44 ± 5.40

0.922

 Creatinine (μmol/L)

83.98 ± 1.77

77.79 ± 2.19

0.187

Hormonal profile

 SHBG (nmol/L)

46.64 ± 50.65

38.93 ± 16.71

0.756

 Testosterone (nmol/L)

14.22 ± 4.62

12.88 ± 5.80

0.158

Tumoral markers

 Total PSA (μg/L)

7.64 ± 4.42

13.14 ± 11.47

0.003

Biofluid biomarker profile

 Semen cytokines (pg/mg of total protein)

  sTWEAK

989.07 ± 624.08

550.54 ± 380.25

0.003

  sCD163

1449.03 ± 2060.7

1392.09 ± 1265.89

0.391

  sFn14

645.31 ± 434.45

609.99 ± 413.28

0.781

  sCXCL5

360.23 ± 376.07

212.72 ± 240.72

0.179

  sCCL7

3.09 ± 3.34

3 ± 2.69

0.767

 Serum cytokines (pg/mL)

  sTWEAK

1118.74 ± 344.32

1331.08 ± 830.51

0.225

  sCD163

346.68 ± 286.15

349.46 ± 276.29

0.976

  sCXCL5

1234.89 ± 630.15

1346.42 ± 703.23

0.439

  sCCL7

2.6 ± 17.62

23.49 ± 107.42

0.508

 Urine cytokines (pg/mg of creatinine)

  sTWEAK

199.62 ± 257.43

128.24 ± 151.58

0.723

  sCD163

166.07 ± 804.1

1173.09 ± 3368.52

0.401

  sFn14

182.5 ± 287.53

159.69 ± 236.24

0.479

  sCXCL5

132.97 ± 142.43

161.98 ± 165.27

0.423

 Semen cell sediment gene expression (arbitrary units, 2−∆∆Ct)

  KLK2

1.12 ± 0.41

0.82 ± 0.45

0.050

  KLK3

1.16 ± 0.75

1.02 ± 0.74

0.529

  CXCR2

2.68 ± 3.6

4.03 ± 3.7

0.089

  CCR3

2.53 ± 3.23

6.31 ± 8.1

0.069

  CD163

6.37 ± 6.57

5.68 ± 5.54

0.796

  Fn14

4.15 ± 2.82

8.52 ± 7.69

0.077

  1. BMI, Body mass index; cc, centiliters; HOMA-IR, homeostatic model assessment for insulin resistance; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; SHBG, sex hormone-binding globulin; PSA, prostate specific antigen; TWEAK, tumor necrosis factor-like weak inducer of apoptosis; CD163, cluster of differentiation 163; Fn14, fibroblast growth factor-inducible 14; CXCL5, C-X-C motif chemokine 5; CCL7, chemokine (C-C motif) ligand 7; CXCR2, C-X-C motif chemokine receptor 2; CCR3, C-C chemokine receptor type 3; KLK2, Kallikrenin-2 gene; KLK3, Kallikrenin-3 gene